Myriad Genetics’ continued investment in molecular residual disease (MRD) testing drives new patents granted 

Myriad Genetics is strengthening its position in the high-growth molecular residual disease (MRD) testing market with newly granted patents that expand protection around its tumor-informed, whole-genome sequencing (WGS)-based Precise^® MRD Test. As of July 2025, three new patents were granted: 

• U.S. patent no. 12,344,901 covers proprietary automated MRD methods. 

• U.S. patent no. 12,351,880 covers broad methods of enriching samples and broad methods of detecting circulating tumor DNA (ctDNA). 

• U.S. patent no. 12,351,879 covers enriched DNA fractions that are prepared in methods of evaluating MRD 

For oncologists and patients, this means more sensitive and reliable monitoring of cancer recurrence and treatment response. These new patents, together with previously issued ones covering automated methods of MRD analysis, patient journey integration, foundational MRD platform technology, and cell-free DNA preparation techniques, collectively strengthen Myriad’s ability to deliver a tumor-informed, high-definition MRD assay to market.  

“These additional patents underscore Myriad’s commitment to innovation and proprietary technology that we believe will help advance cancer care for patients and improve outcomes,” said Brian Donnelly, Chief Commercial Officer, Myriad Genetics. “Our Precise MRD Test will answer two fundamental questions that clinicians and patients have to support cancer care: 1) is treatment working? and 2) has cancer recurred?”  

The Precise^® MRD Test 

Myriad’s Precise MRD Test is an ultra-sensitive tumor-informed assay that is WGS-based. This unique assay enables the custom selection of up to 1,000 targeted variants for deep analysis. The test can be used to monitor ctDNA levels throughout a patient’s clinical cancer care, starting immediately after diagnosis and continuing through treatment and surveillance. 

Precise MRD is available for use in research studies pursued jointly by Myriad and academic or pharmaceutical investigators. The test is currently being evaluated in several high-impact studies. Research highlights include: 

• The Lancet Oncology published a study highlighting the performance of the Precise MRD Test in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). The study demonstrated that circulating tumor DNA (ctDNA) levels were associated with patients’ response to metastasis-directed radiation therapy (MDT). Precise MRD was able to detect ctDNA levels in patients with very low tumor burden. In fact, 94% of patients tested at baseline had ctDNA levels below 100 ppm, which falls in the ultrasensitive testing range. Read more about the MRD findings here. 

• Clinical data from the MONSTAR-SCREEN 3 study demonstrated successful pan-cancer implementation of Myriad’s ultra-sensitive Precise MRD Test to detect and monitor ctDNA in patients. The interim results achieved 100% baseline detection of ctDNA across tumor types, including those traditionally challenging to assess because of low levels of ctDNA in blood. 

• Clinical data highlighting the performance of the Precise MRD test in patients with oligometastatic clear-cell renal cell carcinoma. This study demonstrated that metastasis-directed radiation therapy can help patients delay or avoid systematic treatments without sacrificing outcomes. 

Myriad continues to develop its Precise MRD Test to meet the needs of patients with cancer, academic partners, and biopharma companies.  

Learn more about Precise MRD. 

Safe Harbor Statement 

This blog post contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Myriad’s commitment to innovation and proprietary technology that we believe will help advance cancer care for patients and improve outcomes, for oncologists and patients this means more sensitive and reliable monitoring of cancer recurrence and treatment response, Myriad’s Precise MRD assay will  answer whether treatment is working and whether cancer has recurred, and Myriad’s continuing development of its Precise MRD assay to meet the needs of patients with cancer, academic partners, and biopharma companies. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in Myriad’s filings with the U.S. Securities and Exchange Commission, including Myriad’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in Myriad’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.